Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp in Pediatric Relapsed/Refractory Hematologic Malignancies
NCT05476770Phase 1Recruiting
- Sponsor
- Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of tagraxofusp in hematologic malignancy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 5 more (4 arms), sponsored by Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium. Primary endpoint: Dose Limiting Toxicity. Started Nov 2022; status: recruiting.
02
Drugs
tagraxofusp
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05476770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476770.